1 New Green Flag for Moderna and Merck Stock

There's a new reason to believe that their joint projects are going well.According to some new data revealed by Moderna (MRNA -0.12%) at the American Association for Cancer Research Annual Meeting on April 8, the biotech responsible for the Spikevax coronavirus vaccine may have another blockbuster drug in the works, this time a personalized cancer vaccine (PCV) for head and neck cancers that it's developing in conjunction with Merck (MRK -0.47%).It's a no-brainer that favorable data makes for favorable sent ...